NovoCure (NVCR) Asset Writedowns and Impairment (2014 - 2026)

NovoCure has disclosed Asset Writedowns and Impairment across 13 years of filings, most recently posting $712000.0 for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $712000.0, down 68.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 2.36% YoY), and the FY2025 annual result was $4.9 million, up 318.55% from the prior year.
• Asset Writedowns and Impairment came in at $712000.0 for Q1 2026 at NovoCure, down from $1.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $2.3 million in Q1 2025 to a low of $112000.0 in Q3 2023.
• The 5-year median for Asset Writedowns and Impairment is $216000.0 (2022), against an average of $480588.2.
• Across the five-year window, Asset Writedowns and Impairment plunged 73.02% in 2023 and jumped 1065.46% in 2025, its largest moves.
• NovoCure's Asset Writedowns and Impairment stood at $441000.0 in 2022, then tumbled by 73.02% to $119000.0 in 2023, then surged by 215.13% to $375000.0 in 2024, then surged by 416.27% to $1.9 million in 2025, then plunged by 63.22% to $712000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $712000.0 (Q1 2026), $1.9 million (Q4 2025), and $230000.0 (Q3 2025), per Business Quant data.